| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.2015.1058156 |
| P698 | PubMed publication ID | 26112307 |
| P2093 | author name string | Xin Yao | |
| Yiping Wang | |||
| Zhenglun Liang | |||
| Miao Xu | |||
| Qunying Mao | |||
| Lianlian Bian | |||
| P2860 | cites work | Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: a molecular epidemiological analysis | Q33589447 |
| Coxsackievirus A6 and hand, foot, and mouth disease, Finland | Q33644605 | ||
| Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice | Q33723474 | ||
| Fatal case of enterovirus 71 infection, France, 2007. | Q33800653 | ||
| Circulation of Coxsackievirus A6 in hand-foot-mouth disease in Guangzhou, 2010-2012. | Q34217390 | ||
| Coxsackievirus A16: epidemiology, diagnosis, and vaccine | Q34290731 | ||
| Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q34347924 | ||
| Coxsackievirus A6 and Hand, Foot and Mouth Disease: Three Case Reports of Familial Child-to-Immunocompetent Adult Transmission and a Literature Review | Q34369919 | ||
| Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. | Q34525982 | ||
| Comparative genomic analysis of coxsackievirus A6 strains of different clinical disease entities | Q34540699 | ||
| Four cases of onychomadesis after hand-foot-mouth disease | Q34615404 | ||
| An overview of the evolution of enterovirus 71 and its clinical and public health significance | Q34635602 | ||
| An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. | Q35815014 | ||
| Enterovirus co-infections and onychomadesis after hand, foot, and mouth disease, Spain, 2008. | Q35849010 | ||
| Molecular epidemiology of coxsackievirus A6 associated with outbreaks of hand, foot, and mouth disease in Tianjin, China, in 2013 | Q36239511 | ||
| Antigenic diversity of enteroviruses associated with nonpolio acute flaccid paralysis, India, 2007-2009. | Q36574377 | ||
| Rapid and sensitive identification of RNA from the emerging pathogen, coxsackievirus A6 | Q36594483 | ||
| Eight years of experience with molecular identification of human enteroviruses | Q36747676 | ||
| Hand, foot, and mouth disease caused by coxsackievirus A6, Thailand, 2012 | Q36825218 | ||
| Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial | Q36977606 | ||
| Emergence, circulation, and spatiotemporal phylogenetic analysis of coxsackievirus a6- and coxsackievirus a10-associated hand, foot, and mouth disease infections from 2008 to 2012 in Shenzhen, China | Q37470313 | ||
| Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations | Q37607514 | ||
| Virology, epidemiology, pathogenesis, and control of enterovirus 71. | Q37801742 | ||
| Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases | Q38248866 | ||
| Towards broadly protective polyvalent vaccines against hand, foot and mouth disease. | Q38275640 | ||
| Coxsackievirus A6 and enterovirus 71 causing hand, foot and mouth disease in Cuba, 2011-2013. | Q39007590 | ||
| Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland | Q39734222 | ||
| The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. | Q39827005 | ||
| Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. | Q40025566 | ||
| Hand, foot and mouth disease caused by coxsackievirus A6, Beijing, 2013. | Q40199864 | ||
| An inactivated enterovirus 71 vaccine in healthy children | Q40216677 | ||
| Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. | Q40220160 | ||
| Coxsackievirus A6-related hand foot and mouth disease: skin manifestations in a cluster of adult patients | Q40220340 | ||
| Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria | Q40272154 | ||
| Clinical and epidemiologic features of Coxsackievirus A6 infection in children in northern Taiwan between 2004 and 2009. | Q40326826 | ||
| Nail matrix arrest following hand-foot-mouth disease: a report of five children | Q40624816 | ||
| A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice | Q42211021 | ||
| A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses | Q42222745 | ||
| Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China | Q42226974 | ||
| A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial | Q42231743 | ||
| Hand, foot and mouth disease in Guangdong, China, in 2013: new trends in the continuing epidemic | Q42232862 | ||
| Molecular epidemiology of enterovirus 71, coxsackievirus A16 and A6 associated with hand, foot and mouth disease in Spain | Q42247869 | ||
| Immunogenicity, safety, and immune persistence of a novel inactivated human enterovirus 71 vaccine: a phase II, Randomized, double-blind, placebo-controlled Trial | Q42252095 | ||
| Enterovirus infection among patients admitted to hospital in Hong Kong in 2010: epidemiology, clinical characteristics, and importance of molecular diagnosis. | Q42286192 | ||
| Hand, foot, and mouth disease caused by coxsackievirus a6. | Q42425639 | ||
| Hand, foot, and mouth disease caused by coxsackievirus A6, Japan, 2011 | Q42572768 | ||
| Rapid and highly sensitive coxsackievirus a indirect immunofluorescence assay typing kit for enterovirus serotyping | Q43029336 | ||
| Hand, foot, and mouth disease outbreak and coxsackievirus A6, northern Spain, 2011. | Q43171731 | ||
| Nail matrix arrest in the course of hand, foot and mouth disease | Q43476743 | ||
| The coxsackie virus group | Q45721206 | ||
| The possibility of outbreak control by real-time surveillance with PCR method perfomed immediately--a case study of hand foot and mouth disease outbreak in a day care facility for children | Q48046136 | ||
| Circulation of multiple enterovirus serotypes causing hand, foot and mouth disease in India | Q48054811 | ||
| Molecular typing of enteroviruses associated with viral meningitis in Cyprus, 2000-2002. | Q48085952 | ||
| Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. | Q51797919 | ||
| Epidemic characteristics of hand, foot, and mouth disease in southern China, 2013: coxsackievirus A6 has emerged as the predominant causative agent. | Q51846294 | ||
| Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. | Q51846339 | ||
| Laboratory investigation and phylogenetic analysis of enteroviruses involved in an aseptic meningitis outbreak in Greece during the summer of 2007. | Q54468422 | ||
| P433 | issue | 9 | |
| P921 | main subject | hand, foot and mouth disease | Q652744 |
| Coxsackievirus | Q1138287 | ||
| mouth disease | Q2508462 | ||
| emerging pathogen | Q108429945 | ||
| P304 | page(s) | 1061-1071 | |
| P577 | publication date | 2015-06-25 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide | |
| P478 | volume | 13 |
| Q46270646 | A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles |
| Q38751806 | A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy. |
| Q56875991 | A complex mosaic of enteroviruses shapes community-acquired hand, foot and mouth disease transmission and evolution within a single hospital |
| Q59355694 | A surrogate assay for measuring Coxsackievirus A6 neutralizing antibodies |
| Q55099892 | A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. |
| Q40052398 | Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody |
| Q55140219 | Atypical Presentation of Hand, Foot, and Mouth Disease in an Adult. |
| Q36370340 | Atypical hand, foot and mouth disease due to Coxsackievirus A6 in a traveler returning from Indonesia to Italy |
| Q30391059 | Bioinformatic analysis of non-VP1 capsid protein of coxsackievirus A6. |
| Q57479301 | Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice |
| Q92215747 | Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study |
| Q91704057 | Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China |
| Q102323241 | Coxsackieviruses A6 and A16 associated with hand, foot, and mouth disease in Vietnam, 2008-2017: Essential information for rational vaccine design |
| Q37077006 | Development and evaluation of a non-ribosomal random PCR and next-generation sequencing based assay for detection and sequencing of hand, foot and mouth disease pathogens. |
| Q36159082 | Development and evaluation of a rapid recombinase polymerase amplification assay for detection of coxsackievirus A6. |
| Q40230983 | Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5. |
| Q28076658 | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| Q30383172 | EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). |
| Q92374884 | Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study |
| Q40092889 | Efficacy and safety of interferon-α2b spray in the treatment of hand, foot, and mouth disease: a multicenter, randomized, double-blind trial. |
| Q51783519 | Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam. |
| Q58794294 | Emerging Enteroviruses Causing Hand, Foot and Mouth Disease, China, 2010-2016 |
| Q92355817 | Emerging Hand Foot Mouth Disease in Bangladeshi Children- First Report of Rapid Appraisal on Pocket Outbreak: Clinico-epidemiological Perspective Implicating Public Health Emergency |
| Q38840182 | Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine |
| Q36571245 | Enteroviruses in the early 21st century: new manifestations and challenges |
| Q103826197 | Epidemical and etiological study on hand, foot and mouth disease following EV-A71 vaccination in Xiangyang, China |
| Q33653024 | Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Shijiazhuang City, Hebei province, China, 2009-2012. |
| Q91787907 | Epidemiological and aetiological characteristics of hand, foot, and mouth disease in Sichuan Province, China, 2011-2017 |
| Q40083958 | Epidemiological and etiological characteristics of herpangina and hand foot mouth diseases in Jiangsu, China, 2013-2014. |
| Q36851382 | Full-Genome Sequences of Seven Fatal Enterovirus 71 Strains Isolated in Shenzhen, China, in 2014. |
| Q98160778 | Genetic Variation of Multiple Serotypes of Enteroviruses Associated with Hand, Foot and Mouth Disease in Southern China |
| Q30249022 | Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. |
| Q48092976 | Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention |
| Q37044874 | Hand-Washing: The Main Strategy for Avoiding Hand, Foot and Mouth Disease |
| Q33812693 | Identification and molecular characterization of non-polio enteroviruses from children with acute flaccid paralysis in West Africa, 2013-2014 |
| Q59352025 | Influence of non-polio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from south India |
| Q26769980 | MicroRNA and Pathogenesis of Enterovirus Infection |
| Q92498658 | Molecular epidemiology of enteroviruses in Cyprus 2008-2017 |
| Q37419883 | Molecular epidemiology of human enterovirus 71 at the origin of an epidemic of fatal hand, foot and mouth disease cases in Cambodia |
| Q91227533 | Monitoring of enterovirus diversity in wastewater by ultra-deep sequencing: An effective complementary tool for clinical enterovirus surveillance |
| Q98188945 | Neonatal hand, foot, and mouth disease due to coxsackievirus A6 in Shanghai |
| Q37277158 | Outbreak of hand, foot, and mouth disease caused by coxsackievirus A6 in a Juku in Fengtai District, Beijing, China, 2015 |
| Q66679579 | Recent advances on the role of host factors during non-poliovirus enteroviral infections |
| Q47429887 | Seroepidemiology of coxsackievirus B5 in infants and children in Jiangsu province, China. |
| Q37245341 | Seroprevalence of Enterovirus A71 and Coxsackievirus A16 in Healthy People in Shandong Province, China |
| Q57209987 | Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses |
| Q33750721 | Serotyping and Genetic Characterization of Hand, Foot, and Mouth Disease (HFMD)-Associated Enteroviruses of No-EV71 and Non-CVA16 Circulating in Fujian, China, 2011-2015. |
| Q92577877 | The Clinical and Epidemiological Study of Children with Hand, Foot, and Mouth Disease in Hunan, China from 2013 to 2017 |
| Q90122913 | The Establishment of Infectious Clone and Single Round Infectious Particles for Coxsackievirus A10 |
| Q90345270 | The interplay of autophagy and enterovirus |
| Q89790315 | The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses |
| Q40638141 | Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. |
Search more.